HROW Stock Forecast & Price Target

Harrow Inc's strategic positioning in the ophthalmic pharmaceutical market, particularly through its FDA-approved products and growing presence in biosimilars, is expected to significantly enhance its market share, which has already surpassed 40% in key therapeutic categories. The company's VEVYE product demonstrated robust performance with a 22% quarter-over-quarter revenue growth to $22.6 million in the third quarter of 2025, while also gaining a 10.5% share of the national dry eye disease market. Projections indicate a substantial increase in quarterly revenue run rate to exceed $250 million by the fourth quarter of 2027, supported by ongoing prescription growth momentum, suggesting strong potential for long-term revenue and margin expansion.

Harrow Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily due to the potential inability of its spinout products to generate favorable clinical data or regulatory approval, which could adversely impact valuation. The company also grapples with risks such as lower-than-expected market adoption of its products, difficulty in acquiring new products, and the burden of outstanding debt, which could further hinder its financial stability. Additionally, as a small company with limited resources, Harrow may be compelled to reduce its sales and marketing efforts and seek additional capital, creating further potential for shareholder dilution.